Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SRPT
HoldHot AirSarepta Therapeutics, Inc. · Healthcare · United States · $2.2B · Avg Vol: $64M/d
COMPANY DESCRIPTION
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing precision genetic medicines for rare neuromuscular diseases, particularly Duchenne muscular dystrophy (DMD). The company holds a leadership position in DMD therapeutics with multiple approved RNA-targeted and gene therapies, benefiting from strong intellectual property and orphan drug designations. Its specialized pipeline addresses significant unmet medical needs in ultra-rare conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 933.0M | 1.2B | 1.9B | 2.2B | 33.1% | 2.0B | 1.8B | 1.4B | -20.7% |
| EPS | -8.03 | -5.80 | 2.47 | -7.13 | — | -1.57 | — | — | — |
| Shares | 88.0M | 93.7M | 96.9M | 105.0M | +19.3% | 105.6M | — | — | — |
| Debt | 1.6B | 1.4B | 1.3B | 1.0B | -13.7% | 1.1B | — | — | — |
| Equity | 384.9M | 859.3M | 1.5B | 1.1B | 43.6% | — | — | — | — |
| Op CF | -325.3M | -501.0M | -205.8M | -205.5M | — | 111.0M | — | — | — |
| Inv CF | -1.0B | -165.8M | 755.6M | 69.6M | — | — | — | — | — |
| Fin CF | 232.5M | 125.0M | 124.8M | -168.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SRPT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc.(you) | $2.2B | 46 | Hold |
| SLS | SELLAS Life Sciences Group, Inc. | $2.7B | 44 | Hold |
| URGN | UroGen Pharma Ltd. | $2.1B | 51 | Hold |
| ADMA | ADMA Biologics, Inc. | $2.1B | 53 | Hold |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.1B | 44 | Hold |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.0B | 50 | Hold |
| SEPN | Septerna, Inc. | $1.8B | 52 | Hold |
| VCEL | Vericel Corporation | $2.1B | 56 | Hold |
| OMER | Omeros Corporation | $1.3B | 48 | Hold |
| AGIO | Agios Pharmaceuticals, Inc. | $2.0B | 32 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%